Summary: In the drug development business, deals are as crucial as scientific breakthroughs, with profitable medicines like Keytruda and Enbrel achieving their current success through M&A.
Summary: The FDA expects to decide on Merck’s approval application for clesrovimab by early June, which could position Merck to launch the drug before next fall.
Summary: In a New York Times opinion piece, Witty made his first public comments since last week’s fatal shooting of Thompson.
Summary: Danish studies suggest Ozempic may increase the risk of the rare vision-threatening condition NAION.
Summary: The vaccine maker’s R&D cuts face skepticism amid continued share decline.
